FIVE-MEMBERED HETEROCYCLIC COMPOUND OF OXOCARBOXYLIC ACID AND MEDICAL USE THEREOF Russian patent published in 2025 - IPC C07D231/56 C07D307/54 C07D307/78 C07D333/00 C07D333/24 C07D333/60 C07D333/76 C07D405/04 C07D407/04 C07D409/04 C07D409/14 C07D417/04 C07D471/04 C07D491/48 C07D495/04 A61K31/343 A61K31/357 A61K31/381 A61K31/403 A61K31/404 A61K31/416 A61K31/4184 A61K31/4355 A61K31/4365 A61K31/437 A61P29/00 A61P31/00 A61P35/00 A61P37/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), W is selected from a group consisting of and where V¹, V², V³, V⁴, V⁵, V⁶, V⁷ and V⁸ is independently selected from a group consisting of a hydrogen atom, a halogen, a C1-C6 alkyl group; or V¹ and V², or V³ and V⁴, or V⁵ and V⁶, or V⁷ and V⁸ together with the carbon atom to which they are attached form a C3-C8 cycloalkyl group; U is independently selected from a group consisting of COOR¹, COOH, CN, CONH₂ and , where R¹ is selected from a group consisting of a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C3-C8 cycloalkyl group and a substituted or unsubstituted 3–8-membered saturated or unsaturated heterocyclyl group containing 1 or 2 heteroatoms selected from O; ring A is a five-membered heteroaromatic ring, in which X, Y and Z are each independently selected from a group consisting of C, CH, C-R², NH, N, O and S, where R² is selected from the group consisting of halogen, C1-C6 alkyl group; ring B is selected from the following structures, where R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³ and R²⁴ each is independently selected from the group consisting of a hydrogen atom, a halogen, a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted C1-C6 alkoxy group, an amino group, , a cyano group; wherein, unless otherwise stated, "substituted" refers to substitution with one or more groups selected from the group consisting of a halogen, a hydroxyl group, a carboxyl group, C1-C6 alkylamino group, C1-C6 alkyl group, C1-C6 alkoxy group and a substituted or unsubstituted 3-8-membered saturated or unsaturated heterocyclyl group containing 1 or 2 heteroatoms selected from O and N; wherein substituted in a "substituted group" refers to substitution with one or more groups selected from the group consisting of a hydroxyl group, a C1-C3 alkyl group. Invention also relates to specific compounds, a pharmaceutical composition containing said compounds, methods for preparing them and use thereof to produce a drug for preventing and/or treating diseases associated with type I interferon, .

EFFECT: compounds can be used as a type I interferon secretion regulator for preventing and/or treating diseases associated with type I interferon.

14 cl, 2 dwg, 3 tbl, 125 ex